Speakers

Speech Title : Decoupling Breast Density and Background Parenchymal Enhancement: Distinct Pathways for Bone and Vascular Risk Assessment

Graziella Di Grezia is a Tenure-Track Researcher at Link Campus University, Department of Life Sciences, Health, and Healthcare Professions, Rome, Italy. She is also an ASN Associate Professor (Seconda Fascia) and serves on the board of the Italian Society of Medical and Interventional Radiology (SIRM). She holds an MD with honors, a PhD in Pharmacological Sciences and Clinical and Experimental Medicine, a specialization in Radiodiagnostics, and a Master’s Degree in Breast Diagnostics and Interventional Surgery. Dr. Di Grezia has an extensive research portfolio, with over 100 publications indexed in PubMed and a Scopus h-index of 20. Her scientific expertise spans oncological and abdominal imaging, focusing on advanced techniques such as diffusion-weighted imaging (DWI), contrast-enhanced mammography, and artificial intelligence applications in diagnostic imaging. She is Principal Investigator in clinical research on DWI Breast MRI for dense breast tissue and actively participates in translational studies on gastrointestinal pathologies and tumor imaging. She contributes to the scientific community as a reviewer and editorial board member for multiple international journals, maintaining rigorous standards in scientific publication. Beyond medicine, Dr. Di Grezia is a classical pianist and artist, and founder of the Mail Poetry Project®, bridging creativity with scientific outreach.

Speech Title : Photodynamic therapy and photodetection with 5-aminolevulinic acid.

Dr. Qian Peng is the group leader of photodynamic therapy (PDT) and photodetection (PD) in the Department of Pathology, Oslo University Hospital, Oslo, Norway. He has been involved in developing PDT and PD technology with 5-aminolevulinic acid for over 40 years. In addition, his research activities focus on the combination of radiation (X-ray, UV-A, visible light, ultrasound) with radio-/photo-/sono-sensitisers and/or nanoparticles to develop diagnostic and therapeutic (nano)technologies of cancer.

Speech Title : Medical oncology Palliative medicine

Kunihiko Ishitani, MD, PhD President of Higashi Sapporo Hospital President of the International Research Society of the Sapporo Conference for Palliative and Supportive Care in Cancer (IRS-SCPSC) Kunihiko Ishitani is an MD, PhD with a specialization in medical oncology and palliative medicine. He studied biochemistry as a research fellow in the Department of Biochemistry at AECOM in the 1970s, and immunology as an assistant professor in the Department of Medical Oncology at Sapporo Medical College. In 1983, he established Higashi Sapporo Hospital (240 beds) as the first cancer palliative care hospital in Japan. From the outset, the physicians at Higashi Sapporo Hospital supported his vision and provided both palliative care and cancer treatment as needed. Higashi Sapporo Hospital now cares for approx. 20% of the cancer deaths in Sapporo City (population 1.97 million) each year. At his request, Higashi Sapporo Hospital established a sister-hospital arrangement with Calvary Hospital in New York in 1990, and have been involved in the ongoing exchange of staff. In 1993, Higashi Sapporo Hospital, Calvary Hospital, and MSKCC jointly held the “Hawaii Conference; Cancer Care in the 1990’s Supportive Care Issues”. Based on that experience, he launched the first Japanese Society of Palliative Medicine in Sapporo City in 1996. Since then, he has gone on to organize many palliative care-related conferences in Japan. He organized the first Sapporo Conference for Palliative and Supportive Care in Cancer (SCPSC) in 2014 and assumed the position of president of the IRS-SCPSC. Since then, SCPSC has been held every three years to promote the scientific advancement of palliative oncology and psycho-oncology, with a focus on providing lectures by world experts in each field. Each conference has attracted over 1,000 people from over 20 countries. The fifth conference is scheduled for 2026 under an innovative program. Dr. Ishitani also served as Associate Editor of the BMJSPCare from 2018 to 2021 and as Asian Editor from 2022 to 2024.

Speech Title : ¹⁸⁸Re-AX-188 (Tozaride): Clinical Translation of a Generator-Produced Rhenium-188 Theranostic Targeting SSTR2 in Neuroendocrine and Pediatric Malignancies

Christopher Adams is a serial biotech entrepreneur and inventor whose technologies have reached millions of patients across ophthalmology and oncology. He is a co-inventor of foundational amniotic membrane contact lens technology underlying Prokera (Bio-Tissue) and of nucleic acid amplification technology underlying Cologuard (Exact Sciences), and holds more than 20 U.S. and international patents. He has been nominated for the National Inventors Hall of Fame. Mr. Adams is Founder & CEO of Andarix Pharmaceuticals, where he leads the clinical development of Tozaride (¹⁸⁸Re-AX-188), an SSTR2-targeted theranostic radioligand built on a generator-produced Rhenium-188 platform. Tozaride has received FDA Rare Pediatric Disease designation for neuroblastoma (RPD-2026-1167). In parallel, he serves as Founder & CEO of Anzor Pharmaceuticals (FGF-based therapeutics and phospholipid analogue dermatology), Founder & Chairman of Diopter Technologies (ophthalmic devices), and Founder of KnowYourPerson, Inc. (digital relationship health). A recognized leader at the intersection of translational science, regulatory strategy, and venture creation, Mr. Adams manages a portfolio of more than 40 active patent matters across drug development, medical devices, and digital health. He is based in Somerville, Massachusetts.